The cost of cancer care accelerates because of the growing number of cancer patients and the increasing expenses of drug innovations. The approval of costly second-line therapies like immune checkpoint inhibitors or CAR-T therapies contributes to this trend. Hence, drug repurposing, which uses drugs originally approved for other indications, is emerging as a necessary approach in cancer care, due to its comparatively low innovation and treatment costs and predictable side-effects1.
In this News and Commentary article, we describe our recently published, novel drug repurposing approach for dual targeting of the p53/MDM2 and p53/MDMX interactions followed by the discussion of the selected MDM2/MDMX inhibitors tested in the clinical setting. Lastly, we touch upon recent reports on pharmacological targeting of mutant p53 for improved cancer therapy.
Mutations in the TP53 gene occur in more than 50% of all human cancers and lead to p53 loss or mal-adaptivity. Some of the TP53 mutations are high penetrance mutations driving tumor development in the hereditary cancer predisposition syndrome called Li-Fraumeni syndrome.
Tumors retaining wild-type (wt) TP53 gene, express p53 but the protein is inactivated. MDM2 and MDMX are the most critical regulators of p53 activity2.
The MDM2 protein is the p53 E3 ubiquitin ligase that under cellular stress conditions mono- or polyubiquitinates p53. This facilitates p53 nuclear export and inhibition of transcription activity (monoubiquitination) or ubiquitin-dependent proteasomal degradation of p53 (polyubiquitination). The heterodimerization of MDM2 with its homologue, MDMX protein, enhances p53 ubiquitination and degradation. Unlike MDM2, MDMX does not degrade p53, but through the binding to the p53 N-terminus ablates its transcription function3 (Fig. 1). The amplification of MDM2 and MDM4 genes or aberrant expression of their regulators e.g. Wip1, Akt, ATM provoke p53 inhibition in cancer.
One way to restore the p53 pathway in wt-p53 tumors is to block the p53/MDM2 interactions utilizing small molecules and more recently, stapled peptides.
Small molecule protoporphyrin IX (PpIX) is a metabolite of aminolevulinic acid (ALA), a natural heme precursor, which was approved in 1999 as ALA photodynamic therapy (ALA-PDT) to treat actinic keratosis in combination with light. After the ALA administration, PpIX accumulates in the diseased tissue. In ALA-PDT, PpIX is next excited with the light of a wavelength matching the absorption maximum of the compound (λ = 410 nm) with 10 J/cm2 light dose per treatment. PpIX excitation leads to the accumulation of reactive oxygen species (ROS) and cell death4. Interestingly, the outcome of ALA-PDT can be improved by the pretreatment with 5-fluorouracyl (5-FU) because it induces wt-p53, thus predisposes to stress-induced apoptosis. 5-FU also downregulates ferrochelatase, therefore, inhibits the incorporation of Fe2+ into PpIX ring and induces massive accumulation of PpIX5.
We demonstrated that repurposed, exogenous PpIX (exo-PpIX) induces rapid cancer cell death without light activation6. The mechanism is by binding to the p53 N-terminal domain and inhibition of the p53/MDM2 interactions, however, the exact binding site has to be elucidated7.
In our latest publication in Cell Death Discovery, we showed that exo-PpIX is a dual inhibitor of p53/MDM2 and p53/MDMX interactions and induces apoptosis in B-cell chronic lymphocytic leukemia cells. Using several assays, including yeast-based reporter assay, fluorescent two-hybrid assay (F2H®) and immunoprecipitation, we confirmed previous findings demonstrating that PpIX inhibits p53/MDM2 interactions. Besides, exo-PpIX furthers the disruption of p53/MDMX interactions8 (Fig. 1).
Comparing to a small molecule RITA, originally reported to display antitumor activity by inhibiting the p53/MDM2 interactions9, exo-PpIX inhibits proliferation and induces apoptosis in B-cell chronic lymphocytic leukemia cells (B-CLL) more efficiently and without affecting healthy blood cells8. A recent study by Szade et al.10 reports that exogenous cobalt PpIX increases the concentration of granulocyte colony stimulating factor (G-CSF) and mobilizes a higher number of mature granulocytes and functional hematopoietic stem cells compared with recombinant G-CSF. Thus, both of the above reported PpIX activities, namely inhibition of p53/MDM2/MDMX interactions and efficient mobilization of cells from the bone marrow to the blood, make exo-PpIX a very promising drug for repurposing in oncology. In particular, it might be of therapeutic benefit to introduce exo-PpIX to treat wt-p53 hematological malignancies. This is due to the high toxicity of current treatments in these cancers reflected by severe neutropenia and increased need for transfusions, which can be decreased with PpIX. Besides, dual targeting of cancers’ vulnerabilities may help to decrease the incidence of the relapsed disease.
Other strategies to target p53/MDM2 interactions converge solely on targeted inhibition of MDM2 protein. The earliest MDM2 antagonist, nutlin (Hoffman‐La Roche), rationally-designed cis‐imidazoline compound, binds to the hydrophobic cleft of the MDM2 and mimicks p53 residues in the MDM2 binding motif; Phe19, Trp23, and Leu2611. Idasanutlin (RG73388), the most advanced derivative of nutlin, has shown a promising result in Phase I trial in patients with acute myeloid leukemia (AML)12 and has advanced to Phase III trial for relapsed/refractory AML (https://clinicaltrials.gov/show/NCT02545283). AMG-232, a selective and high-affinity piperidinone MDM2 inhibitor, is in Phase I clinical trials for glioblastoma, sarcoma and myeloid malignancies13.
Despite the successful advancement to the clinical trial phase, the development of resistance to MDM2 inhibitors, which induces mutations in TP5314 and triggers an urgent need for the establishment of more effective drug combinations for wt-TP53 cancers.
One way to overcome the risk of development of resistance is dual targeting of MDM2 and MDMX, which we study. Several inhibitors of MDMX were reported to date, however, the dual, small-molecule inhibitors of MDM2 and MDMX have not been developed yet. Nowadays, stapled peptides, which bind both to MDM2 and MDMX, see the renascence in targeting wt-p53 tumors. The most advanced, ALRN-6924 peptide, α-helical p53 stapled peptidomimetic, is a potent MDM2/MDMX-antagonist tested in Phase I clinical trials for advanced solid tumors and hematological malignancies15.
Despite the efforts, tumors overexpressing MDM2 and MDMX are still a great unmet medical need. Therefore, they constitute high-priority indications for drug repurposing approach described by us8.
p53 acts together with p73 and p63 proteins in tumor suppression4. In addition to p53, exo-PpIX activates p73 by binding to N-terminal domain and inhibits the p73/MDM2 and p73/MDMX interactions16. In our recent work in Cell Death Discovery, we confirmed that both p53 and p73 were activated by exo-PpIX in B-CLL cells. In addition to wt-p53, the exo-PpIX activates p73 and induces ROS through inhibition of thioredoxin reductase in mutant TP53 cancers17. Thus, we reason that exo-PpIX (and Verteporfin) might be a promising drug candidate to target TP53 mutant cancers.
Mutant p53-targeting strategies are in clinical development. Small-molecule APR-246 (PRIMA-1Met, Aprea Therapeutics, Inc.), a mutant p53 re-activating compound, is the only mutant p53-targeting molecule in the Phase III clinical trial. APR-246 is converted to reactive Michael acceptor, methylene quinuclidinone (MQ). MQ binds covalently to cysteines in p53 via alkylation of thiol groups, stabilizes it and refolds mutant p53 to the wt-like conformation. This restores wt-p53 function and induces cancer cells death18. Besides p53, MQ reacts with and inhibits thioredoxin reductase, which induces ROS in cancer cells19. It was tested in TP53-mutated myelodysplastic syndromes in combination with azacitidine (https://clinicaltrials.gov/show/NCT03745716). Preliminary results of the Phase Ib/II trials in TP53-mutated myelodysplastic syndrome in combination with azacitidine showed 74% overall response rate (ORR) and 59% complete remission (CR) rate in 27 evaluable MDS patients (https://clinicaltrials.gov/show/NCT03588078). In a second trial, 88% ORR and 61% CR were reported in 33 evaluable MDS patients. Seventeen (52%) evaluable MDS patients discontinued therapy to pursue stem cell transplant (https://clinicaltrials.gov/show/NCT03072043)20.
In conclusion, novel repurposing of PpIX for dual targeting of the p53/MDM2 and p53/MDMX interactions might be a promising alternative to target wt-p53 tumors. Further studies using advanced preclinical models are needed to evaluate its therapeutic potential in TP53 mutant cancers.
References
Pantziarka, P., Bouche, G. & Andre, N. “Hard” drug repurposing for precision oncology: the missing link? Front. Pharmacol. 9, 637–639 (2018).
Montes de Oca Luna, R., Wagner, D. S. & Lozano, G. Rescue of early embryonic lethality in mdm2-deficient mice by deletion of p53. Nature 378, 203–206 (1995).
Vogelstein, B., Lane, D. & Levine, A. J. Surfing the p53 network. Nature 408, 307–310 (2000).
Acedo, P. & Zawacka-Pankau, J. p53 family members—important messengers in cell death signaling in photodynamic therapy of cancer? Photochem. Photobiol. Sci. 14, 1390–1396 (2015).
Maytin, E. V. et al. 5-Fluorouracil enhances protoporphyrin IX accumulation and lesion clearance during photodynamic therapy of actinic keratoses: a mechanism-based clinical trial. Clin. Cancer Res. 24, 3026–3035 (2018).
Bednarz, N., Zawacka-Pankau, J., Kowalska, A. & Protoporphyrin, I. X. induces apoptosis in HeLa cells prior to photodynamic treatment. Pharm. Rep. 59, 474–479 (2007).
Zawacka-Pankau, J. et al. Protoporphyrin IX interacts with wild-type p53 protein in vitro and induces cell death of human colon cancer cells in a p53-dependent and -independent manner. J. Biol. Chem. 282, 2466–2472 (2007).
Jiang, L., Malik, N., Acedo, P. & Zawacka-Pankau, J. Protoporphyrin IX is a dual inhibitor of p53/MDM2 and p53/MDM4 interactions and induces apoptosis in B-cell chronic lymphocytic leukemia cells. Cell Death Discov. 5, 77–88 (2019).
Issaeva, N. et al. Small molecule RITA binds to p53, blocks p53-HDM-2 interaction and activates p53 function in tumors. Nat. Med. 10, 1321–1328 (2004).
Szade, A. et al. Cobalt protoporphyrin IX increases endogenous G-CSF and mobilizes HSC and granulocytes to the blood. EMBO Mol. Med. 11, e09571–e09587 (2019).
Vassilev, L. T. et al. In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science 303, 844–848 (2004).
Reis, B. et al. Acute myeloid leukemia patients’ clinical response to idasanutlin (RG7388) is associated with pre-treatment MDM2 protein expression in leukemic blasts. Haematologica 101, e185–e188 (2016).
Sun, D. et al. Discovery of AMG 232, a potent, selective, and orally bioavailable MDM2-p53 inhibitor in clinical development. J. Med. Chem. 57, 1454–1472 (2014).
Skalniak, L. et al. Prolonged Idasanutlin (RG7388) Treatment Leads to the Generation of p53-Mutated Cells. Cancers 10, 396–412 (2018).
Carvajal, L. A. et al. Dual inhibition of MDMX and MDM2 as a therapeutic strategy in leukemia. Science Transl. Med. 10, eaao3003–eaao3014 (2018).
Sznarkowska, A. et al. Reactivation of TAp73 tumor suppressor by protoporphyrin IX, a metabolite of aminolevulinic acid, induces apoptosis in TP53-deficient cancer cells. Cell Div. 13, 10–21 (2018).
Acedo, P., Fernandes, A. & Zawacka-Pankau, J. Activation of TAp73 and inhibition of TrxR by Verteporfin for improved cancer therapy in TP53 mutant pancreatic tumors. Future Sci. OA 5, FSO366–FSO377 (2019).
Lambert, J. M. et al. PRIMA-1 reactivates mutant p53 by covalent binding to the core domain. Cancer Cell 15, 376–388 (2009).
Eriksson, S. E., Ceder, S., Bykov, V. J. N. & Wiman, K. G. p53 as a hub in cellular redox regulation and therapeutic target in cancer. J. Mol. Cell Biol. 11, 330–341 (2019).
Aprea Therapeutics, Inc. Aprea therapeutics receives FDA fast track designation and orphan drug designation for APR-246 for the Treatment of Myelodysplastic Syndromes (MDS). http://www.aprea.com (2019).
Acknowledgements
The authors would like to apologize for not citing other authors due to space restriction.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
The authors declare that they have no conflict of interest.
Additional information
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Edited by I. Amelio
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
About this article
Cite this article
Jiang, L., Zawacka-Pankau, J. The p53/MDM2/MDMX-targeted therapies—a clinical synopsis. Cell Death Dis 11, 237 (2020). https://doi.org/10.1038/s41419-020-2445-9
Received:
Revised:
Accepted:
Published:
DOI: https://doi.org/10.1038/s41419-020-2445-9
This article is cited by
-
p53 biology and reactivation for improved therapy in MDS and AML
Biomarker Research (2024)
-
The synergy of the XPO1 inhibitors combined with the BET inhibitor INCB057643 in high-grade B-cell lymphoma via downregulation of MYC expression
Scientific Reports (2023)
-
Recent insights into the microRNA-dependent modulation of gliomas from pathogenesis to diagnosis and treatment
Cellular & Molecular Biology Letters (2022)
-
IFITM3 promotes malignant progression, cancer stemness and chemoresistance of gastric cancer by targeting MET/AKT/FOXO3/c-MYC axis
Cell & Bioscience (2022)
-
Transcription profiling of feline mammary carcinomas and derived cell lines reveals biomarkers and drug targets associated with metabolic and cell cycle pathways
Scientific Reports (2022)